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In this study, the duration of the QRS complex during 
ventricular pacing was used as an index of intraventric-
ular conduction to quantitate the rate-dependent effects 
of intravenous lidocaine, procainamide and amiodarone. 
Right ventricular apical pacing (15 to 20 beats) was per-
formed at cycle lengths of 600, 500, 400, 350, 300, 275 
and 250 ms, before and 5 minutes after the intravenous 
administration of lidocaine in 11 patients (serum level 
3.2 ± 0.8 JLg/ml [mean ± SD)), procainamide in 14 
patients (serum level 8.2 ± 1.9 JLg/ml) and amiodarone 
in 12 patients (serum level 3.9 ± 1.2 JLg/ml). Electro-
cardiographic recordings were made at a paper speed 
of 150 mm/s. QRS duration was measured in a blinded 
fashion, with reproducibility within 5 %. 
In the control state, QRS duration was the same at 
all paced cycle lengths. After lidocaine, procainamide 
and amiodarone administration, the shortest paced cycle 
length with complete ventricular capture was 250 ± 0, 
275 ± 38 and 264 ± 20 ms, respectively. At a paced 
cycle length of 600 ms, the increase in QRS duration 
Lidocaine, procainamide and amiodarone have been shown 
to block sodium channels in a rate-dependent fashion in 
isolated muscle preparations (1-4). Depression in the max-
imal rate of rise of the action potential upstroke by these 
drugs is accentuated during rapid stimulation because as the 
rate increases, there is less time for sodium channels to 
recover from block. Because conduction in ventricular myo-
cardium is dependent predominantly on the fast sodium 
current, depression of intraventricular conduction by lido-
caine, procainamide and amiodarone would also be expected 
to occur in a rate-dependent fashion. Accordingly, lidocaine 
From the Division of Cardiology, Department of Internal Medicine, 
University Hospitals, University of Michigan Medical Center, Ann Arbor, 
Michigan. Manuscript received December 28, 1985; revised manuscript 
received February 12, 1985, accepted March 29, 1985. 
Address for reprints: Fred Morady, MD, Division of Cardiology, W-
11511, University Hospitals, University of Michigan Medical Center, 1405 
East Ann Street, Ann Arbor, Michigan 48109. 
© 1985 by the American College of Cardiology 
compared with the control state was 1 ± 2 % with lido-
caine (p > 0.05), 21 ± 7% with procainamide (p < 
0.001) and 6 ± 6% with amiodarone (p < 0.05). At the 
shortest paced cycle length with complete capture, the 
increase in QRS duration compared with the control 
state was 20 ± 6% with lidocaine (p < 0.001), 42 ± 
11 % with procainamide (p < 0.001) and 26 ± 4% with 
amiodarone (p < 0.001). 
The acute effects of lidocaine, procainamide and 
amiodarone on intraventricular conduction are rate-de-
pendent, with the effects of intravenous amiodarone being 
more similar to those of lidocaine than those of pro-
cainamide. Prolongation of conduction occurs at a slower 
rate with procainamide than with lidocaine or amioda-
rone. These data suggest that each of these three drugs 
blocks sodium channels, and that recovery from block 
is slower with procainamide than with lidocaine or 
amiodarone. 
(J Am Coil Cardiol 1985;6:179-85) 
and procainamide have been found to cause rate-dependent 
slowing of intraventricular conduction in animal prepara-
tions (5,6). However, few studies have investigated the rate-
dependent effects of these drugs on intraventricular con-
duction in human subjects. Two studies (7,8) concluded that 
lidocaine did not have a rate-dependent effect on intraven-
tricular conduction. In a preliminary report (9), the rate-
dependent effects on QRS duration of intravenous procain-
amide and lidocaine, and oral amiodarone and mexiletine, 
were assessed in small numbers of patients (three to five). 
To date, the rate-dependent effects of intravenous amio-
darone on intraventricular conduction in human subjects have 
not been investigated. In this study, the acute rate-dependent 
effects on intraventricular conduction of intravenous lido-
caine, procainamide and amiodarone were quantitated and 
compared. The duration of the QRS complex during ven-
tricular pacing was used as an index of intraventricular 
conduction. 
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Methods 
Patients studied. Thirty-seven patients (24 men and 13 
women) who underwent electrophysiologic testing because 
of ventricular tachycardia or unexplained syncope were the 
subjects of this study. Their mean age (± SO) was 58 ± 
IS years. Twenty-three patients had coronary artery disease, 
eight had a dilated cardiomyopathy, one had mitral valve 
prolapse and five had no identifiable structural heart disease. 
Pacing protocol. Electrophysiologic testing was per-
formed with the patients in the fasting, un sedated state after 
informed consent had been obtained, at least four half-lives 
after discontinuation of all antiarrhythmic drugs. One to 
three 6F quadripolar electrode catheters were positioned at 
various locations in the right atrium or ventricle, as clinically 
indicated. The pacing protocol (outlined later) was per-
formed in the course of electropharmacologic testing in pa-
tients who had inducible ventricular tachycardia, or on com-
pletion of a normal electrophysiologic study in patients who 
had unexplained syncope. 
A quadripolar electrode catheter was positioned in the 
apex of the right ventricle. Pacing was performed at a current 
strength of twice diastolic threshold (pulse width 2 ms) with 
a programmable stimulator (Bloom Associates, Ltd.). In all 
patients, the pacing threshold was less than I rnA. Right 
ventricular pacing was performed for at least IS to 20 beats 
at cycle lengths of 600, 500, 400, 350, 300, 275 and 250 
rtis'. The last five QRS complexes of each pacing train were 
recorded on an Electronics for Medicine VRI2 recorder, at 
a paper speed of 150 mm/s. Electrocardiographic leads Vb 
land III were recorded. This pacing protocol was performed 
immediately before and 5 minutes after the administration 
'dfiIidocaine in II patients, procainamide in 14 patients and 
amiodarone in 12 patients. The electrode catheter positioned 
in the right ventricular apex was not moved in the interim. 
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The following intravenous dosing protocols were used: 
I) lidocaine: 100 mg over 2 minutes, followed by three 50 
mg boluses at 5 minute intervals; a 2 mg/min continuous 
infusion was started immediately after the initial 100 mg 
bolus; 2) procainamide: 1 g at a rate of 50 mg/min; and 3) 
amiodarone: 10 mg/kg at a rate of 50 mg/min. A blood 
sample for determination of the appropriate serum drug level 
was drawn after completion of the pacing protocol (10 to 
15 minutes). The mean serum levels of lidocaine, procain-
amide and amiodarone were 3.2 ± 0.8 /Lg/ml (range 1.7 
to 4.3),8.2 ± I.9/Lg/ml (range 6.1 to 10.2) and 3.9 ± 
1.2/Lg/ml (range 2.1 to 4.8), respectively. 
Data analysis. The duration of the QRS complex was 
measured from electrocardiographic lead III which, in all 
cases, provided the best definition of the onset and termi-
nation of the QRS complex. Patients were not included in 
this study if the onset or termination of the QRS complex 
was not well defined in any of the three monitored electro-
cardiographic leads. The duration of the last QRS complex 
of each paced train was measured in a blinded fashion by 
one of us (F.M.). Reproducibility, as assessed by indepen-
dent measurement of the QRS complexes by another one 
of us (L.O.) was within 5%. 
All values are expressed as mean ± standard deviation. 
Statistical analysis was performed with paired or unpaired 
t test, as appropriate. 
Results 
In the control state, there was no significant difference 
in the QRS duration during ventricular pacing at the various 
cycle lengths. The shortest cycle length resulting in com-
plete ventricular capture was 260 ± 15 ms. The rate-
dependent effects of lidocaine, procainamide and amio-
* 
Figure 1. Rate-dependent effects of lidocaine on 
QRS duration. The mean QRS duration (± 1 SD) 
is shown before and after lidocaine, during ven-
tricular pacing at cycle lengths of 600 to 250 ms. 
The number of patients in whom there was complete 
ventricular capture at each paced cycle length is 
shown in parentheses below the corresponding cycle 
length. The mean QRS durations before and after 
lidocaine at each paced cycle length were compared 
with a paired t test. 
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Figure 2. Rate-dependent effects of procainamide 
on QRS duration. Format as in Figure I, 
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darone on QRS duration are displayed in Figures I to 6 and 
Table I, 
Effects of lidocaine (Fig. 1 and 4). After the admin-
istration of lidocaine, at a paced cycle length of 600 ms, 
there was no change in QRS duration compared with the 
control state (164 ± 24 versus 162 ± 24 ms, p > 0,05), 
In all II patients who received lidocaine, there was complete 
ventricular capture at a paced cycle length of 250 ms, After 
lidocaine, at a paced cycle length of 250 ms, there was a 
Figure 3. Rate-dependent effects of amiodarone on 
QRS duration, Format as in Figure L 
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21 % increase in QRS duration compared with the control 
state (194 ± 30 versus 160 ± 24 ms, p < 0.001). 
Effects of procainamide (Fig. 2 and 5). After procain-
amide administration, at a paced cycle length of 600 ms, 
there was a 21 % increase in QRS duration compared with 
the control state (193 ± 30 versus 160 ± 15 ms, p < 
0.00 I). In nine patients, the shortest cycle length resulting 
in complete ventricular capture was 250 ms, and in five 
patients, it was 300 or 350 ms (mean 273 ± 12). At the 
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shortest paced cycle length resulting in complete ventricular 
capture, there was a 41 % increase in QRS duration com-
pared with the control state (232 ± 37 versus 164 ± 25 
ms, p < 0.(01). 
Effects of amiodarone (Fig. 3 and 6). After amioda-
rone administration, at a paced cycle length of 600 ms, there 
was a 6% increase in QRS duration compared with the 
control state (160 ± 26 versus 152 ± 29 ms, p < 0.05). 
In eight patients, the shortest paced cycle length resulting 
in complete ventricular capture was 250 ms, and in three 
patients, it was 275 or 300 ms (mean 262 ± 21). At the 
shortest paced cycle length resulting in complete ventricular 
capture, there was a 26% increase in QRS duration com-
pared with the control state (190 ± 38 versus ISO ± 28 
ms, p < 0.(01). 
Comparison of drug effects (Table 1). At a paced cycle 
length of 600 ms, the increase in QRS duration compared 
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Figure 4. Typical example of the rate-dependent 
effect of lidocaine on QRS duration. The last two 
or three paced complexes of a train of 15 to 20 
stimuli are shown. In the control state, QRS du-
ration was 153 ms at a paced cycle length of 600 
and 250 ms. After lidocaine administration (serum 
level 3.4 ILgiml) , the QRS duration was unchanged 
at a paced length of 600 ms, but increased by 22% 
to 187 ms at a paced cycle length of 250 ms. 
with the control state after procainamide was significantly 
greater than after lidocaine or amiodarone (p < 0.001 for 
both), and the increase after amiodarone was significantly 
greater than that after lidocaine (p < 0.001). At the shortest 
paced cycle length resulting in complete ventricular capture, 
the increase in QRS duration compared with the control 
state was significantly greater after procainamide than after 
lidocaine or amiodarone (p < 0.001 for both), and the 
increase after amiodarone was significantly greater than that 
after lidocaine (p < 0.05). 
Discussion 
The results of this study indicate that intravenous lido-
caine, procainamide and amiodarone all acutely prolong 
intraventricular conduction in a rate-dependent manner. Be-
cause sodium channel blockade is reflected by intraventric-
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Figure S. Typical example of the rate-dependent 
effect of procainamide on QRS duration. In the 
control state, QRS duration was 167 ms and was 
not rate-dependent. After procainamide administra-
tion (serum level 7.9 ILgiml), QRS duration in-
creased by 20% to 200 ms at a paced cycle length 
of 600 ms, and by 36% to 227 ms at a paced cycle 
length of 300 ms. At paced cycle lengths shorter 
than 300 ms, there was 2: I ventricular capture. 
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Figure 6. A typical example of the rate-dependent 
effect of intravenous amiodarone on QRS duration. 
In the control state, QRS duration was 173 ms at a 
paced cycle length of 600 and 250 ms. After amio-
darone administration (serum level 3.8 J,Lg/ml), QRS 
duration increased by 12% to 193 ms at a paced 
cycle length of 600 ms, and by 31 % to 227 ms at 
a paced cycle length of 275 ms. At a paced cycle 
length of 250 ms, there was 2: I ventricular capture. ryV--
73ms 
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ular conduction, these findings are consistent with rate-de-
pendent sodium channel blockade found previously (1-4) 
to occur in vitro in response to lidocaine, procainamide and 
amiodarone. 
Results of prior studies. In a preliminary report (9), 
the rate-dependent effects on QRS duration of intravenous 
procainamide and lidocaine and oral amiodarone and mex-
iletine were tested in groups of three to five patients each. 
With each drug, the QRS duration at a short ventricular 
pacing cycle length (290 ± 34 ms) was 10 to 12% greater 
than at a ventricular pacing cycle length of 500 ms. When 
the results of our study were analyzed in a similar fashion, 
intravenous lidocaine, procainamide and amiodarone were 
found to increase the QRS duration at a ventricular pacing 
cycle length of 300 ms to a value 10 to 11 % greater than 
at a cycle length of 500 ms. Our results therefore confirm 
these preliminary observations; however, they also highlight 
the contrasting effects of the three drugs since the study 
compared pre- and post-drug QRS duration at various pacing 
Table 1. Percent Change in QRS Duration After Lidocaine, 
Procainamide and Amiodarone Administration at a Ventricular 
Paced Cycle Length of 600 ms and at the Shortest Paced Cycle 
Length Resulting in Complete Ventricular Capture 
Percent change in QRS 
Paced CL 600 ms 
Shortest paced CL 
with complete capture 
Shortest paced CL with 
complete capture (ms) 
p Values 
Lidocaine Procainamide Amiodarone 
(II patients) (14 patients) (12 patients) 
(A) I ± 2 (B) 21 ± 7 (C) 6 ± 6 
(D) 20 ± 6 (E) 42 ± II (F) 26 ± 4 
(G) 250 ± 0 (H) 275 ± 38 (I) 264 ± 20 
p < 0.001 = D vs. A, E vs. B, F vs. C, B vs. A, B vs. C, C vs. 
A, E vs. D, E vs. F; p < 0.01 = H vs. G; P < 0.05 = F vs. D; 
P > 0.05 = H vs. I, I vs. G. 
*Values are expressed as mean ± SD. CL = cycle length. 
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cycle lengths, rather than only QRS duration at long and 
short pacing cycle lengths after drug administration. 
Effects of lidocaine. Lidocaine administration had little 
or no measurable effect on intraventricular conduction at a 
cycle length of 600 ms; depression of intraventricular con-
duction by lidocaine was manifest only at the more rapid 
pacing rates. In contrast, two prior studies (7,8) of the 
effects of lidocaine on intraventricular conduction in human 
subjects concluded that this drug did not have rate-dependent 
effects on conduction. However, the dose of lidocaine ad-
ministered in these prior studies was only 50 to 150 mg and 
may not have yielded an adequate serum drug level. In 
addition, in these studies, intraventricular conduction was 
assessed by measurement of QRS duration during atrial 
pacing. The assessment of rate-dependent effects was there-
fore limited by the occurrence of atrioventricular nodal 
Wenckebach block. The use of ventricular pacing in our 
study avoided this limitation and allowed the attainment of 
more rapid rates than is possible with atrial pacing. 
Effects of procainamide. In contrast to the effects of 
lidocaine, procainamide slowed conduction to a significant 
degree (21%), even at a paced cycle of 600 ms. This sug-
gests that there is more rapid recovery of blocked sodium 
channels with lidocaine than with procainarnide, such that 
at an interstimulus interval of 600 ms, recovery of sodium 
channels blocked by lidocaine is complete or nearly com-
plete and no measurable prolongation of intraventricular 
conduction is observed. These findings are compatible with 
the results of in vitro studies (2) indicating that the recovery 
half-time of sodium channels blocked by lidocaine is 140 
ms, whereas the corresponding recovery half-time in the 
case of procainamide is 1.8 seconds. These findings also 
explain why procainamide increases QRS duration during 
sinus rhythm whereas lidocaine does not (10), even though 
both drugs block sodium channels. 
Effects of intravenous amiodarone. The acute rate-de-
pendent effects of intravenous arniodarone on intraventric-
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ular conduction were intermediate to the effects of lidocaine 
and procainamide, with mild prolongation (6%) at a paced 
cycle length of 600 ms, and a maximal prolongation of 26% 
at the more rapid stimulation rates. The acute effects of 
intravenous amiodarone more closely resembled the effects 
of lidocaine than those of procainamide. In contrast, in vitro 
studies (4) have indicated that the time constant for recovery 
of sodium channels from amiodarone blockade is long (1.8 
seconds), suggesting that significant prolongation of intra-
ventricular conduction should occur at a paced cycle length 
of 600 ms. There are three possible explanations for this 
apparent discrepancy. First, although the serum amiodarone 
level in every patient tested with this drug was within or 
above the range of serum levels reported to be "therapeutic" 
for intravenous amiodarone (2 to 3 p,g/ml) (11) because 
the pacing protocol was performed only 5 minutes after 
completion of the amiodarone infusion, there may not have 
been adequate time for amiodarone to move from the in-
travascular into the tissue compartment. Second, because 
sodium channel blockade caused by admiodarone admin-
istration is both rate-dependent and voltage-dependent (4), 
the discrepancy may be attributed to voltage differences 
between the intact heart and isolated muscle preparations. 
Finally, there may be a difference between the rate-depen-
dent effects of amiodarone in animals and human subjects. 
Intravenous amiodarone in treatment of ventricular 
tachycardia. There has been disagreement regarding the 
acute efficacy of intravenous amiodarone for the treatment 
of ventricular tachycardia. Some studies (11-16) reported 
that intravenously administered amiodarone is efficacious 
in the acute suppression of both spontaneous and induced 
ventricular tachycardia and ventricular premature depolar-
izations. However, other studies (17, 18) concluded that in-
travenous amiodarone has no acute antiarrhythmic effects 
on ventricular arrhythmias. Although some investigators (4) 
concluded that amiodarone has primary effects on the myo-
cardial action potential which could account for its antiar-
rhythmic effects, others (19,20) found that the antiar-
rhythmic effects of amiodarone may be mediated by a 
disturbance in thyroid metabolism. The results of our study 
suggest that amiodarone does have a direct depressant effect 
on conduction through ventricular myocardium. This effect 
occurred acutely and cannot be explained by an alteration 
in thyroid metabolism. Intravenous amiodarone has little or 
no acute effect on ventricular refractoriness (15,16,18,21). 
Therefore, rate-dependent effects of amiodarone on intra-
ventricular conduction may provide a potential mechanism 
of action by which intravenous amiodarone suppresses ven-
tricular arrhythmias. 
No comments were made in this study on the relation 
between QRS duration during sinus rhythm, presence of 
bundle branch block or duration of HV interval and rate-
dependent effects on conduction because very few patients 
studied had bundle branch block or a prolonged HV interval. 
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Conclusions. Lidocaine, procainamide and amiodarone 
all acutely prolong intraventricular conduction in a rate-
dependent fashion. The findings of this study provide in 
vivo corroboration of in vitro data indicating that each of 
these drugs blocks sodium channels. The rate-dependent 
response to these drugs suggests that recovery of blocked 
sodium channels occurs most rapidly with lidocaine, and 
least rapidly with procainamide. 
We express our gratitude to Lisa Hackbarth for her excellent secretarial 
assistance. 
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